Inspite of acquiring an entire response with optimal induction therapy, minimal residual illness generally persists, necessitating consolidation therapy to mitigate the risk of relapse by eliminating residual sickness. In people who have received seven+3 induction therapy, consolidation therapy is initiated with large-dose cytarabine, often known